A detailed history of Franklin Street Advisors Inc transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Franklin Street Advisors Inc holds 20,000 shares of SUPN stock, worth $681,400. This represents 0.04% of its overall portfolio holdings.

Number of Shares
20,000
Previous 20,140 0.7%
Holding current value
$681,400
Previous $539,000 15.77%
% of portfolio
0.04%
Previous 0.04%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 09, 2024

SELL
$25.77 - $35.16 $3,607 - $4,922
-140 Reduced 0.7%
20,000 $624,000
Q2 2023

Jul 13, 2023

BUY
$29.91 - $38.73 $4,187 - $5,422
140 Added 0.7%
20,140 $605,000
Q1 2022

Apr 18, 2022

SELL
$28.51 - $32.9 $32,643 - $37,670
-1,145 Reduced 5.41%
20,000 $646,000
Q4 2021

Jan 26, 2022

SELL
$26.37 - $34.22 $501,030 - $650,180
-19,000 Reduced 47.33%
21,145 $617,000
Q3 2021

Oct 22, 2021

BUY
$23.54 - $31.39 $423,720 - $565,020
18,000 Added 81.28%
40,145 $1.07 Million
Q2 2021

Aug 05, 2021

SELL
$26.72 - $33.19 $53,440 - $66,380
-2,000 Reduced 8.28%
22,145 $682,000
Q3 2020

Oct 21, 2020

SELL
$20.2 - $25.05 $90,900 - $112,725
-4,500 Reduced 15.71%
24,145 $503,000
Q1 2019

May 14, 2019

SELL
$32.77 - $41.99 $1,802 - $2,309
-55 Reduced 0.19%
28,645 $1 Million
Q4 2018

Feb 14, 2019

SELL
$30.84 - $49.51 $15,420 - $24,755
-500 Reduced 1.71%
28,700 $953,000
Q4 2017

Jan 10, 2018

SELL
$36.4 - $42.6 $7,280 - $8,520
-200 Reduced 0.68%
29,200 $1.16 Million
Q3 2017

Oct 11, 2017

BUY
$36.75 - $49.65 $1.08 Million - $1.46 Million
29,400
29,400 $1.18 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.82B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Franklin Street Advisors Inc Portfolio

Follow Franklin Street Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Franklin Street Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Franklin Street Advisors Inc with notifications on news.